SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

27 Oct 2023 Evaluate
The September 2023 quarter revenue stood at Rs. 9942.40 millions, up 19.95% as compared to Rs. 8288.70 millions during the corresponding quarter last year.Net profit surges 63.03% to Rs. 771.60  millions  from Rs. 473.30 millions in the quarter ended September 2023.The company reported a good operating profit of 1752.40 millions compared to 1645.30 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 9942.40 8288.70 19.95 18406.70 15753.40 16.84 34432.20 33404.20 3.08
Other Income 890.80 1177.00 -24.32 1157.60 2243.10 -48.39 3410.70 2247.90 51.73
PBIDT 1752.40 1645.30 6.51 2185.10 2050.20 6.58 4386.00 7000.70 -37.35
Interest 282.20 285.60 -1.19 620.20 488.70 26.91 1158.70 572.90 102.25
PBDT 1470.20 1290.10 13.96 1564.90 1491.90 4.89 3157.70 6277.00 -49.69
Depreciation 508.30 471.10 7.90 1012.00 918.90 10.13 1920.80 1653.70 16.15
PBT 961.90 819.00 17.45 552.90 573.00 -3.51 1236.90 4623.30 -73.25
TAX 190.30 345.70 -44.95 114.90 270.90 -57.59 541.90 947.90 -42.83
Deferred Tax 112.90 244.50 -53.82 37.50 169.70 -77.90 154.20 -160.30 -196.19
PAT 771.60 473.30 63.03 438.00 302.10 44.99 695.00 3675.40 -81.09
Equity 13229.50 11933.20 10.86 13229.50 11933.20 10.86 11933.20 11859.10 0.62
PBIDTM(%) 17.63 19.85 -11.21 11.87 13.01 -8.78 12.74 20.96 -39.22

Piramal Pharma Share Price

148.75 -0.15 (-0.10%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×